180 related articles for article (PubMed ID: 23312613)
1. Atorvastatin ameliorates podocyte injury in patients with type 2 diabetes complicated with dyslipidemia.
Takemoto M; Ishikawa T; Onishi S; Okabe E; Ishibashi R; He P; Kobayashi K; Fujimoto M; Kawamura H; Yokote K
Diabetes Res Clin Pract; 2013 Apr; 100(1):e26-9. PubMed ID: 23312613
[TBL] [Abstract][Full Text] [Related]
2. Therapy with atorvastatin versus rosuvastatin reduces urinary podocytes, podocyte-associated molecules, and proximal tubule dysfunction biomarkers in patients with type 2 diabetes mellitus: a pilot study.
Vlad A; Vlad M; Petrica L; Ursoniu S; Gadalean F; Popescu R; Vlad D; Dumitrascu V; Gluhovschi G; Gluhovschi C; Velciov S; Bob F; Matusz P; Secara A; Simulescu A; Jianu DC
Ren Fail; 2017 Nov; 39(1):112-119. PubMed ID: 27841047
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia.
Tehrani S; Mobarrez F; Antovic A; Santesson P; Lins PE; Adamson U; Henriksson P; Wallén NH; Jörneskog G
Thromb Res; 2010 Sep; 126(3):e225-31. PubMed ID: 20637495
[TBL] [Abstract][Full Text] [Related]
4. Effect of NCB-02, atorvastatin and placebo on endothelial function, oxidative stress and inflammatory markers in patients with type 2 diabetes mellitus: a randomized, parallel-group, placebo-controlled, 8-week study.
Usharani P; Mateen AA; Naidu MU; Raju YS; Chandra N
Drugs R D; 2008; 9(4):243-50. PubMed ID: 18588355
[TBL] [Abstract][Full Text] [Related]
5. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
6. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients.
Sorof J; Berne C; Siewert-Delle A; Jørgensen L; Sager P;
Diabetes Res Clin Pract; 2006 Apr; 72(1):81-7. PubMed ID: 16246447
[TBL] [Abstract][Full Text] [Related]
7. The effect of atorvastatin and simvastatin on vitamin D, oxidative stress and inflammatory marker concentrations in patients with type 2 diabetes: a crossover study.
Sathyapalan T; Shepherd J; Atkin SL; Kilpatrick ES
Diabetes Obes Metab; 2013 Aug; 15(8):767-9. PubMed ID: 23356580
[TBL] [Abstract][Full Text] [Related]
8. Statin treatment of patients with diabetes.
Eisenbarth GS
Curr Diab Rep; 2005 Apr; 5(2):83. PubMed ID: 15794908
[No Abstract] [Full Text] [Related]
9. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
[TBL] [Abstract][Full Text] [Related]
10. Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Grigoropoulou P; Eleftheriadou I; Zoupas C; Makrilakis K; Papassotiriou I; Margeli A; Perrea D; Katsilambros N; Tentolouris N
Diab Vasc Dis Res; 2014 Jan; 11(1):26-33. PubMed ID: 24154932
[TBL] [Abstract][Full Text] [Related]
11. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.
Otto C; Otto B; Frost RJ; Vogeser M; Pfeiffer AF; Spranger J; Parhofer KG
Acta Diabetol; 2007 Jun; 44(2):65-8. PubMed ID: 17530469
[TBL] [Abstract][Full Text] [Related]
12. Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.
Gumprecht J; Gosho M; Budinski D; Hounslow N
Diabetes Obes Metab; 2011 Nov; 13(11):1047-55. PubMed ID: 21812889
[TBL] [Abstract][Full Text] [Related]
13. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
Shioji K; Izuhara M; Mitsuoka H; Uegaito T; Matsuda M;
Cardiovasc Ther; 2014 Jun; 32(3):97-104. PubMed ID: 24456217
[TBL] [Abstract][Full Text] [Related]
14. Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).
Adolescent type 1 Diabetes cardio-renal Intervention Trial Research Group
BMC Pediatr; 2009 Dec; 9():79. PubMed ID: 20017932
[TBL] [Abstract][Full Text] [Related]
15. Alternate-day dosing of atorvastatin: effects in treating type 2 diabetic patients with dyslipidaemia.
Ferrer-García JC; Pérez-Silvestre J; Martínez-Mir I; Herrera-Ballester A
Acta Diabetol; 2006 Nov; 43(3):75-8. PubMed ID: 17143784
[TBL] [Abstract][Full Text] [Related]
16. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
17. Effects of atorvastatin and rosuvastatin on renal function in patients with type 2 diabetes mellitus.
Lai CL; Chou HW; Chan KA; Lai MS
Am J Cardiol; 2015 Mar; 115(5):619-24. PubMed ID: 25591893
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin in patients with type 2 diabetes mellitus undergoing dialysis.
Robinson JG
N Engl J Med; 2005 Oct; 353(17):1858-60; author reply 1858-60. PubMed ID: 16252415
[No Abstract] [Full Text] [Related]
20. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus.
Freed MI; Ratner R; Marcovina SM; Kreider MM; Biswas N; Cohen BR; Brunzell JD;
Am J Cardiol; 2002 Nov; 90(9):947-52. PubMed ID: 12398960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
